In addition, a remarkable heterogeneity in disease outcomes and metastatic patterns is typically observed among patients, highlighting the need for a deeper understanding of the ROS1+ NSCLC tumor biology (13, 14). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.